Sector News

Perrigo to Buy Omega Pharma for $4.5 Billion

November 6, 2014
Life sciences
Perrigo Co. PLC has agreed to buy Belgium-based Omega Pharma NV in a bid to expand its portfolio of over-the-counter drugs and broaden its market presence throughout Europe.
 
The companies said the deal was valued at 3.6 billion euros, or $4.5 billion, which includes 2.48 billion euros in equity and 1.1 billion euros in debt. About 25% of the equity price will be paid in Perrigo stock to Omega founder Marc Coucke, while the remaining 75% will be funded through a combination of cash and debt, they added.
 
Perrigo said it has secured a 1.75 billion-euro bridge loan from J.P. Morgan Chase Bank and Barclays.
 
Omega, the fifth-largest entity in the $30 billion European OTC market, made about $1.6 billion in revenue in the 12-month period ended Sept. 30, the companies said. It boasts a portfolio of about 2,000 products, including treatments for colds, pain and gastrointestinal problems.
 
Perrigo said it expects the deal to be immediately accretive to its adjusted per-share earnings, with double-digit accretion coming during its 2016 fiscal year.
 
The companies expect the acquisition to close in the first quarter of next year.
 
Also Thursday, Perrigo unveiled weaker-than-expected results for the most recent quarter.
 
For the period ended Sept. 27, the company posted $96.3 million in profit, or 72 cents a share, down from $111.4 million, or $1.18 a share. Excluding certain items, per-share earnings were $1.40.
 
Net sales rose about 2% to $951.5 million.
 
Analysts polled by Thomson Reuters had projected $1.44 a share in earnings and $998 million in revenue.
 
By Michael Calia
 

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach